OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
P/E ratio for OncoCyte Corporation (OCX)
P/E ratio as of 2023: -0.69
According to OncoCyte Corporation's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.69. At the end of 2022 the company had a P/E ratio of -0.48.
P/E ratio history for OncoCyte Corporation from 2013 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -0.69 |
| 2022 | -0.48 |
| 2021 | -3.01 |
| 2020 | -5.23 |
| 2019 | -5.17 |
| 2018 | -3.32 |
| 2017 | -7.25 |
| 2016 | -16.75 |
| 2015 | -15.03 |
| 2014 | -10.52 |
| 2013 | -15.01 |